Swiss National Bank Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Swiss National Bank grew its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 22.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 85,400 shares of the company’s stock after acquiring an additional 15,700 shares during the period. Swiss National Bank’s holdings in Vera Therapeutics were worth $3,612,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in VERA. AlphaQuest LLC purchased a new stake in Vera Therapeutics in the fourth quarter worth $34,000. KBC Group NV increased its stake in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Moors & Cabot Inc. bought a new position in shares of Vera Therapeutics in the 4th quarter worth about $220,000. E Fund Management Co. Ltd. lifted its position in Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock valued at $262,000 after acquiring an additional 1,130 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. grew its holdings in Vera Therapeutics by 109.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company’s stock worth $416,000 after purchasing an additional 4,914 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Down 0.7 %

Shares of NASDAQ:VERA opened at $26.95 on Wednesday. The stock’s fifty day moving average price is $31.35 and its 200-day moving average price is $39.13. Vera Therapeutics, Inc. has a 1 year low of $25.99 and a 1 year high of $51.61. The company has a market cap of $1.72 billion, a P/E ratio of -10.33 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Guggenheim lifted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JPMorgan Chase & Co. dropped their target price on Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 price target for the company. Finally, Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $64.67.

Insider Activity

In other news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now owns 143,603 shares of the company’s stock, valued at $5,993,989.22. This represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 21.70% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.